Market Analysis - Unibest Industrial Co., Ltd.

Blogs

Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

The overlooked opportunity in heart health: Generic EPA
2023-11-30

Heart disease continues to be the primary cause of death globally, claiming upwards of 17 million lives each year. Statins have evolved as an acceptable course for reducing LDL cholesterol and cardiovascular risk. Yet, a significant residual risk remains. With the increasing prevalence of obesity, d Read More
The Growing Global Burden of Diabetes
2023-11-13

November 14th marks World Diabetes Day, a day to raise awareness of the impact of diabetes globally. This year's theme is "Access to Diabetes", focusing on the importance of knowing your risk for type 2 diabetes and ensuring access to proper information and care. In honor of World Diabetes Day 2023, Read More
Forecasting the Global Demand for Ubrogepant
2023-10-19

In the dynamic realm of the pharmaceutical industry, where the drive for improved patient outcomes meets the reality of a global market, understanding and forecasting demand is key. Unibest has developed a step-by-step approach to calculating the market potential for specific pharmaceuticals. In thi Read More
The Chronic Impact of Migraine: The Need for New Treatment Options
2023-10-18

Migraine is a highly prevalent and disabling neurological disease, affecting approximately 12% of adults worldwide. For those living with migraines, the condition can severely impact their quality of life and ability to function. Migraine attacks involve moderate to severe throbbing head pain, often Read More
Lenacapavir: Market Analysis of the First-in-Class Capsid Inhibitor
2023-10-13

In August 2022, Gilead announced that the European Commission (EC) has granted marketing authorization for Sunlenca (Lenacapavir), an innovative treatment for adults with multi-drug resistant HIV infection. The treatment works in combination with other antiretroviral(s) when it isn't Read More
A Breif Drug Development Analysis of Antiretrovirals
2023-09-26

Antiretroviral drugs have evolved significantly over time, with new drugs continuously being developed. The analysis below provides some insights into the development timeline, the focus on drug classes, and the use of drugs in combination formulations.Evolution of Drug ClassesThe following timeline Read More
Trilaciclib, The First-in-Class Myeoprotection: Market, Advantages, and Competitions
2023-09-15

In recent years, the concept of myeloprotection—protecting bone marrow from the damaging effects of chemotherapy—has emerged as a crucial component in cancer therapy. In the face of this evolving landscape, G1 Therapeutics' trilaciclib (marketed as COSELA®) stands out. Trilaciclib is the first thera Read More
Pralsetinib and NSCLC
2023-09-14

Compounds with CAS RN 2097133-17-8, CAS RN 2778223-52-0 and CAS RN 35277-02-2 can be used to synthesize Read More